RO7049389 + RO7020531 + nucleos(t)ide

This is an investigational combination therapy comprising **RO7049389** (a hepatitis B virus core protein allosteric modulator), **RO7020531** (a toll-like receptor 7 agonist), and a **nucleos(t)ide analogue** (NUC) for the treatment of **chronic hepatitis B (CHB)**. - **RO7049389** is a **small molecule** that binds to the HBV core protein, disrupting proper capsid assembly, suppressing viral replication, and depleting functional core protein, showing potent and selective antiviral activity with favorable safety and pharmacokinetics profiles[2][5][6]. - **RO7020531** is a **small molecule TLR7 agonist** that stimulates the innate immune response, enhancing antiviral activity in combination with other agents[3][4]. - **Nucleos(t)ide analogues** inhibit the HBV polymerase to prevent viral replication and are considered backbone therapies in HBV management. This combination is being evaluated for efficacy, safety, and its potential to achieve sustained viral suppression and loss of hepatitis B surface antigen (HBsAg) in patients with CHB[1][4]. The developer is Hoffmann-La Roche, and the therapy is administered orally (RO7049389, RO7020531, NUC).

Other names

CpAM + TLR7 + nucleos(t)ideHBV combination therapy (RO7049389/RO7020531/NUC)